Biggest changeGAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies. Year ended December 31, 2023 2022 2021 Reconciliation of net income (loss) attributable to Nutex Health Inc. to Adjusted EBITDA: Net income (loss) attributable to Nutex Health Inc. $ (45,786,614) $ (424,780,446) $ 132,593,328 Depreciation and amortization 17,591,572 13,131,374 7,662,464 Interest expense, net 16,317,869 12,490,260 6,196,026 Income tax expense (5,067,084) 13,090,905 965,731 Allocation to noncontrolling interests (5,546,263) (4,837,514) (5,751,066) EBITDA (22,490,520) (390,905,421) 141,666,483 Facility closing costs 217,266 - - Acquisition costs 43,464 3,885,666 3,553,716 Stock-based compensation 2,835,971 189,581 - Rescission of warrant exercise - 1,243,059 - Impairment of assets 29,082,203 - - Impairment of goodwill 1,139,297 398,135,038 - Adjusted EBITDA $ 10,827,681 $ 12,547,923 $ 145,220,199 50 Table of Contents Three months ended Three months ended December 31, 2023 December 31, 2022 Unaudited Unaudited Reconciliation of net income (loss) attributable to Nutex Health Inc. to Adjusted EBITDA: Net loss attributable to Nutex Health Inc. $ (31,617,897) $ (14,752,177) Depreciation and amortization 4,682,724 3,271,861 Interest expense, net 4,236,553 2,862,071 Income tax expense (2,998,554) 1,805,176 Allocation to noncontrolling interests (2,045,390) (392,290) EBITDA (27,742,564) (7,205,359) Stock-based compensation 637,159 54,166 Rescission of warrant exercise - 1,243,059 Impairment of assets 29,082,203 - Impairment of goodwill 1,139,297 - Adjusted EBITDA $ 3,116,095 $ (5,908,134) Significant Accounting Policies Revenue recognition . Hospital division – Our hospital division recognizes net patient service revenue for contracts with patients and in most cases a third-party payor (commercial insurance, workers compensation insurance or, in limited cases, Medicare/Medicaid).
Biggest changeGAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies. 45 Table of Contents Year ended December 31, 2024 2023 2022 Reconciliation of net income (loss) attributable to Nutex Health Inc. to Adjusted EBITDA: Net income (loss) attributable to Nutex Health Inc. $ 52,179,168 $ (45,786,614) $ (424,780,446) Depreciation and amortization 18,971,972 17,591,572 13,131,374 Interest expense, net 19,932,015 16,317,869 12,490,260 Income tax expense (benefit) 14,476,821 (5,067,084) 13,090,905 Allocation to noncontrolling interests (7,176,312) (5,546,263) (4,837,514) EBITDA 98,383,664 (22,490,520) (390,905,421) Facility closing costs - 217,266 - Acquisition costs - 43,464 3,885,666 Loss on warrant liability 1,608,973 - - Stock-based compensation 16,631,898 2,835,971 189,581 Rescission of warrant exercise - - 1,243,059 Impairment of assets 3,887,216 29,082,203 - Impairment of goodwill 3,197,391 1,139,297 398,135,038 Adjusted EBITDA $ 123,709,142 $ 10,827,681 $ 12,547,923 Three months ended Three months ended December 31, 2024 December 31, 2023 Unaudited Unaudited Reconciliation of net income (loss) attributable to Nutex Health Inc. to Adjusted EBITDA: Net income (loss) attributable to Nutex Health Inc. $ 61,695,604 $ (31,617,897) Depreciation and amortization 5,280,488 4,682,724 Interest expense, net 5,052,081 4,236,553 Income tax expense (benefit) 8,608,746 (2,998,554) Allocation to noncontrolling interests (2,195,888) (2,045,390) EBITDA 78,441,031 (27,742,564) Loss on warrant liability 536,264 - Stock-based compensation 14,680,454 637,159 Impairment of assets (11,640) 29,082,203 Impairment of goodwill - 1,139,297 Adjusted EBITDA $ 93,646,109 $ 3,116,095 Significant Accounting Policies Revenue recognition . Hospital division – Our hospital division recognizes patient service revenue for contracts with patients, and in most cases, patients with out of network benefits with a third-party payor, such as, commercial insurance, workers compensation insurance or, in limited cases, Medicare/Medicaid.
Such leases are typically on a triple net basis where our hospital division is responsible for all operating costs, repairs and taxes on the facilities. Finance lease income is recognized outside of segment operating income as other income by the Real Estate Entities.
Such leases are typically on a triple net basis where our hospital division is responsible for all operating costs, repairs and taxes on the facilities. Finance lease income is recognized outside of segment operating income as other income by the Real Estate Entities.
In periods before our merger with Clinigence, Nutex Health Holdco LLC and the Nutex Subsidiaries were pass-through entities treated as partnerships for U.S. federal income tax purposes. No provision for federal income taxes was provided for these periods as federal taxes were obligations of these companies’ members.
In periods before our merger with Clinigence, Nutex Health Holdco LLC and the Nutex Subsidiaries were pass-through entities treated as partnerships for U.S. federal income tax purposes. No provision for federal income taxes was provided for these periods as federal taxes were obligations of these companies’ members.
After the merger, Nutex Health Holdco LLC became a wholly-owned subsidiary of Clinigence and is included in its consolidated corporate tax filings. We recognized a non-cash charge of $21.3 million to income tax expense during 2022 for the change in tax status of Nutex Health Holdco LLC.
After the merger, Nutex Health Holdco LLC became a wholly-owned subsidiary of Clinigence and is included in its consolidated corporate tax filings. We recognized a non-cash charge of $21.3 million to income tax expense during 2022 for the change in tax status of Nutex Health Holdco LLC.
On average, greater than 90% of our net patient service revenue are paid by insurers, federal agencies, and other non-patient third parties. The remaining revenues are paid by our patients in the form of copays, deductibles, and self-payment.
On average, greater than 90% of our net patient service revenue is paid by insurers, federal agencies, and other non-patient third parties. The remaining revenues are paid by our patients in the form of copays, deductibles, and self-payment.
Our 2023 results were principally affected by: • A non-cash asset impairment charge of $29.1 million and a non-cash goodwill impairment charge of $1.1 million due to the closures of two facilities in January 2023 and two facilities in January 2024; • Increase in revenue primarily related to increased collections and improved acuity; • Issuance in March 2023 of 1,000,000 common shares for total expense of $1.9 million to Apollo Medical Holdings, Inc. for IPA managerial services; • Higher interest expense in 2023 principally as a result of the Yorkville Pre-paid Advance issuance; • Higher overall costs in general and administrative costs due primarily to increased corporate staffing and support to meet the Company’s public company obligations. Adjusted EBITDA for 2023 was $10.8 million as compared to $12.5 million for 2022.
Our 2023 results were principally affected by: 41 Table of Contents • A non-cash asset impairment charge of $29.1 million and a non-cash goodwill impairment charge of $1.1 million due to the closures of two facilities in January 2023 and two facilities in January 2024; • Increase in revenue primarily related to increased collections and improved acuity; • Issuance in March 2023 of 1,000,000 common shares for total expense of $1.9 million to Apollo Medical Holdings, Inc. for IPA managerial services; • Higher interest expense in 2023 principally as a result of the Yorkville Pre-paid Advance issuance; • Higher overall costs in general and administrative costs due primarily to increased corporate staffing and support to meet the Company’s public company obligations. Adjusted EBITDA for 2023 was $10.8 million as compared to $12.5 million for 2022.
The Company’s indebtedness at December 31, 2023 is presented in Item 8, “Financial Statements – Note 8 – Debt” and our lease obligations are presented in Item 8, “Financial Statements—Note 9 – Leases.” We have entered into private debt arrangements with banking institutions for the purchase of equipment and to provide working capital and liquidity through cash and lines of credit.
The Company’s indebtedness at December 31, 2024 is presented in Item 8, “Financial Statements – Note 8 – Debt” and our lease obligations are presented in Item 8, “Financial Statements—Note 9 – Leases.” We have entered into private debt arrangements with banking institutions for the purchase of equipment and to provide working capital and liquidity through cash and lines of credit.
During 2023, we deconsolidated one Real Estate Entity after the third-party lenders released our guarantees of associated mortgage loans. Revenue and operating expenses of consolidated Real Estate Entities are not significant since the extent of these entities’ operations is to own facilities leased to our hospital division entities which are financed by a combination of contributed equity by related parties and third-party mortgage indebtedness.
During 2023, we deconsolidated one Real Estate Entity after the third-party lenders released our guarantees of associated mortgage loans. 42 Table of Contents Revenue and operating expenses of consolidated Real Estate Entities are not significant since the extent of these entities’ operations is to own facilities leased to our hospital division entities which are financed by a combination of contributed equity by related parties and third-party mortgage indebtedness.
There is no financing component associated with payments due from insurers or patients. 51 Table of Contents Population health management division – The population health management division recognizes revenue for capitation and management fees for services to IPAs and physician groups and for the licensing, training, and consulting related to our cloud-based proprietary technology. Capitation revenue consists primarily of capitated fees for medical services provided by physician-owned entities we consolidate as VIEs.
There is no financing component associated with payments due from insurers or patients. Population health management division – The population health management division recognizes revenue for capitation and management fees for services to IPAs and physician groups and for the licensing, training, and consulting related to our cloud-based proprietary technology. Capitation revenue consists primarily of capitated fees for medical services provided by physician-owned entities we consolidate as VIEs.
The Company has the right at any time for any reason to terminate the Agreement. Off-Balance Sheet Arrangements As of December 31, 2023, we had no material off-balance sheet arrangements. Non-GAAP Financial Measures Adjusted EBITDA.
The Company has the right at any time for any reason to terminate the Agreement. Off-Balance Sheet Arrangements As of December 31, 2024, we had no material off-balance sheet arrangements. Non-GAAP Financial Measures Adjusted EBITDA.
In such instances, we may be required to consolidate these new Real Estate Entities in our financial statements as VIEs. 45 Table of Contents Corporate and other costs. Corporate and other costs in 2023 included general and administrative expenses totaling $33.2 million, impairment losses of $30.2 million due to facility closures and stock-based compensation of $2.2 million.
In such instances, we may be required to consolidate these new Real Estate Entities in our financial statements as VIEs. Corporate and other costs. Corporate and other costs in 2023 included general and administrative expenses totaling $33.2 million, impairment losses of $30.2 million due to facility closures and stock-based compensation of $2.2 million.
This charge provides for the accumulated net deferred tax liabilities representing the differences between the book and tax bases of Nutex Health Holdco LLC’s assets and liabilities as of the April 1, 2022 change in tax status. 48 Table of Contents At the time of our merger with Clinigence, Clinigence had a full valuation allowance against its deferred tax assets.
This charge provides for the accumulated net deferred tax liabilities representing the differences between the book and tax bases of Nutex Health Holdco LLC’s assets and liabilities as of the April 1, 2022 change in tax status. At the time of our merger with Clinigence, Clinigence had a full valuation allowance against its deferred tax assets.
Refer to Non-GAAP Financial Measures discussed below for a definition and reconciliation of Adjusted EBITDA. The items affecting revenue and start-up costs of four new hospitals in 2023 contributed significantly to the decline in Adjusted EBITDA in the 2023 period. 44 Table of Contents A discussion of our segment results is included below. Hospital Division.
Refer to Non-GAAP Financial Measures discussed below for a definition and reconciliation of Adjusted EBITDA. The items affecting revenue and start-up costs of four new hospitals in 2023 contributed significantly to the decline in Adjusted EBITDA in the 2023 period. A discussion of our segment results is included below. Hospital Division.
Beginning with the second quarter of 2022, our financial statements are presented on a consolidated basis and include Clinigence. Except where the context indicates otherwise, (i) references to “we,” “us,” “our,” or the “Company” refer, for periods prior to the completion of the merger, to Nutex Health Holdco LLC and its subsidiaries, (ii) references the “Nutex Health” for periods following the completion of the merger, refer to Nutex Health Inc. and its subsidiaries and (ii) references to “Clinigence” refer to Clinigence Holdings, Inc. and its subsidiaries prior to the completion of the merger. 39 Table of Contents Overview Nutex Health Inc. is a physician-led, healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division.
Beginning with the second quarter of 2022, our financial statements are presented on a consolidated basis and include Clinigence. Except where the context indicates otherwise, (i) references to “we,” “us,” “our,” or the “Company” refer, for periods prior to the completion of the merger, to Nutex Health Holdco LLC and its subsidiaries, (ii) references the “Nutex Health” for periods following the completion of the merger, refer to Nutex Health Inc. and its subsidiaries and (ii) references to “Clinigence” refer to Clinigence Holdings, Inc. and its subsidiaries prior to the completion of the merger. Overview Nutex Health Inc. is a physician-led, healthcare services and operations company with 24 hospital facilities in 11 states (hospital division), and a primary care-centric, risk-bearing population health management division.
Since the second quarter of 2022, we deconsolidated 18 Real Estate Entities after the third-party lenders released our guarantees of associated mortgage loans, leaving three Real Estate Entities as current VIEs consolidated in our financial statements. The Company has no direct or indirect ownership interest in the Physician LLCs or Real Estate Entities, so 100% of the equity for these entities is shown as noncontrolling interest in the consolidated balance sheets and statements of operations. The population health management division includes our management services organizations and a healthcare information technology company providing a cloud-based platform for healthcare organizations.
Since the second quarter of 2022, we deconsolidated 18 Real Estate Entities after the third-party lenders released our guarantees of associated mortgage loans, leaving three Real Estate Entities as current VIEs consolidated in our financial statements. 36 Table of Contents The Company has no direct or indirect ownership interest in the Physician LLCs or Real Estate Entities, so 100% of the equity for these entities is shown as noncontrolling interest in the consolidated balance sheets and statements of operations. The population health management division includes our management services organizations.
These amounts are net of appropriate discounts giving recognition to differences between the Company’s charges and reimbursement rates from third party payors. Patient service net revenues earned by the Company are recognized at a point in time when the services are provided, net of adjustments and discounts.
These amounts are net of appropriate discounts giving recognition to differences between the Company’s charges and reimbursement rates from third party payors. 46 Table of Contents Hospital revenues earned by the Company are recognized at a point in time when the services are provided to patients, net of adjustments and discounts.
The Company’s performance obligations are to provide emergency health care services primarily on an outpatient basis. Net patient service revenues are recorded at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care.
The Company’s performance obligations are to provide emergency health care services primarily on an outpatient basis. Patient service revenues are recorded at the amount that reflects the consideration that the Company expects to be paid for providing patient care.
We do not have an equity interest in this VIE but consolidate it since we are the primary beneficiary of its operations under our management services contract with them.
Capitation revenue is recognized by our consolidated VIE, AHISP. We do not have an equity interest in this VIE but consolidate it since we are the primary beneficiary of its operations under our management services contract with them.
The Company regularly is in the process of constructing new facilities. Generally, our hospital facilities are responsible for the leasehold buildout and equipment while the associated Real Estate Entity procures the land, if any, and constructs a new or remodeled facility.
Generally, our hospital facilities are responsible for the leasehold buildout and equipment while the associated Real Estate Entity procures the land, if any, and constructs a new or remodeled facility.
As there are no contractual rates established with insurance entities, revenues are estimated based on the “usual and customary” charges allowed by insurance payors using historical collection experience, historical trends of refunds and payor payment adjustments (retractions).
As there are no contractual rates established with insurance entities, revenues are estimated based on the “usual and customary” charges allowed by insurance payors using historical collection experience, historical trends of refunds and payor payment adjustments (retractions). Revenue from the Medicare program is based on reimbursement rates set by governmental authorities.
The population health management division owns and operates provider networks such as independent physician associations (“IPAs”) and offers a cloud-based proprietary technology platform to IPAs which aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers. We employ 800 full-time employees, contract 230 doctors at our facilities and partner with over 1,700 physicians within our networks.
The population health management division owns and operates provider networks such as independent physician associations (“IPAs”) and offers a cloud-based proprietary technology platform to IPAs which aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers. At December 31, 2024, we employed approximately 800 full-time employees, contracted 255 doctors at our facilities and partnered with over 2,100 physicians within our networks.
We generally operate as an out-of-network provider and, as such, do not have negotiated reimbursement rates with insurance companies. The following tables present the allocation of the transaction price with the patient between the primary patient classification of insurance coverage: 40 Table of Contents Year ended December 31, 2023 2022 2021 Insurance 93% 89% 96% Self pay 4% 9% 3% Workers compensation 2% 1% 1% Medicare/Medicaid 1% 1% 0% Total 100% 100% 100% The population health management division recognizes revenue for capitation and management fees for services to IPAs and physician groups and for the licensing, training, and consulting related to our cloud-based proprietary technology.
We generally operate as an out-of-network provider and, as such, do not have negotiated reimbursement rates with insurance companies. The following tables present the allocation of the transaction price with the patient between the primary patient classification of insurance coverage: Year ended December 31, 2024 2023 2022 Insurance 94% 93% 89% Self pay 3% 4% 9% Workers compensation 2% 2% 1% Medicare/Medicaid 1% 1% 1% Total 100% 100% 100% The population health management division recognizes revenue for capitation and management fees for services to IPAs.
Immediately thereafter, in the merger, each unit representing an equity interest in Nutex Health Holdco LLC was converted into the right to receive 3.571428575 shares of common stock, or an aggregate of 592,791,712 shares of common stock. The Merger was accounted for as a reverse business combination under U.S. GAAP.
Immediately thereafter, in the merger, each unit representing an equity interest in Nutex Health Holdco LLC was converted into the right to receive shares of common stock of Clinigence Holdings, Inc. (n/k/a Nutex Health, Inc.). The Merger was accounted for as a reverse business combination under U.S. GAAP.
During the second quarter of 2022, we deconsolidated 17 Real Estate Entities after the third-party lenders released our guarantees of associated mortgage loans. Revenue and operating expenses of consolidated Real Estate Entities are not significant since the extent of these entities’ operations is to own facilities leased to our hospital division entities which are financed by a combination of contributed equity by related parties 47 Table of Contents and third-party mortgage indebtedness.
As of December 31, 2024, we provided guarantees to the indebtedness of two Real Estate Entities. 40 Table of Contents Revenue and operating expenses of consolidated Real Estate Entities are not significant since the extent of these entities’ operations is to own facilities leased to our hospital division entities which are financed by a combination of contributed equity by related parties and third-party mortgage indebtedness.
Revenue from the Medicare program is based on reimbursement rates set by governmental authorities. Patients who have health care insurance may also have discounts applied related to their copayment or deductible. Estimates of contractual adjustments and discounts are determined by major payor classes for outpatient revenues based on historical experience.
The Company is reimbursed from third party payors under various methodologies based on the level of care provided. Patients who have health care insurance may also have discounts applied related to their copayment or deductible. Estimates of contractual adjustments and discounts are determined by major payor classes for outpatient revenues based on historical experience.
Activity within our business segments is significantly impacted by demand for healthcare services we provide, competition for these services in each of the market areas we serve, and the legislative changes discussed above. 43 Table of Contents Following is our results of operations for the periods shown: Year ended December 31, 2023 2022 2021 Revenue: Hospital division $ 218,070,397 $ 198,508,245 $ 331,531,311 Population health management division 29,575,919 20,786,061 - Total revenue 247,646,316 219,294,306 331,531,311 Segment operating income (loss): Hospital division 36,332,772 15,034,269 179,280,958 Population health management division (1,558,601) 387,469 - Total segment operating income 34,774,171 15,421,738 179,280,958 Corporate and other costs: Facilities closing costs 217,266 - - Acquisition costs 43,464 3,885,666 3,553,716 Stock-based compensation 2,835,971 189,581 - Impairment of assets 29,082,203 - - Impairment of goodwill 1,139,297 398,135,038 - General and administrative expenses 33,229,718 19,810,607 5,462,344 Total corporate and other costs 66,547,919 422,020,892 9,016,060 Interest expense 16,317,869 12,490,260 6,196,026 Other expense (income) 399,182 559,299 (5,422,144) Income (loss) before taxes (48,490,799) (419,648,713) 169,491,016 Income tax expense (benefit) (5,067,084) 13,090,905 965,731 Net income (loss) (43,423,715) (432,739,618) 168,525,285 Less: net income (loss) attributable to noncontrolling interests 2,362,899 (7,959,172) 35,931,957 Net income (loss) attributable to Nutex Health Inc. $ (45,786,614) $ (424,780,446) $ 132,593,328 Adjusted EBITDA $ 10,827,681 $ 12,547,923 $ 145,220,199 Year Ended December 31, 2023 Compared to Year Ended December 31, 2022 We reported a net loss attributable to Nutex Health Inc. of $45.8 million, or a loss of $0.07 per share, for 2023 as compared with a net loss attributable to Nutex Health Inc. of $424.8 million, or a loss of $0.67 per share, for 2022.
Activity within our business segments is significantly impacted by the demand for healthcare services we provide, competition for these services in each of the market areas we serve, and the legislative changes discussed above. 38 Table of Contents Following is our results of operations for the periods shown: Year ended December 31, 2024 2023 2022 Revenue: Hospital division $ 449,063,683 $ 218,070,397 $ 198,508,245 Population health management division 30,884,950 29,575,919 20,786,061 Total revenue 479,948,633 247,646,316 219,294,306 Segment operating income (loss): Hospital division 195,539,009 36,336,211 15,035,130 Population health management division 1,380,659 (1,558,601) 387,469 Real estate division (658,391) (3,439) (861) Total segment operating income 196,261,277 34,774,171 15,421,738 Corporate and other costs: Facilities closing costs - 217,266 - Acquisition costs - 43,464 3,885,666 Stock-based compensation 16,631,898 2,835,971 189,581 Impairment of assets 3,887,216 29,082,203 - Impairment of goodwill 3,197,391 1,139,297 398,135,038 General and administrative expenses 41,923,972 33,229,718 19,810,607 Total corporate and other costs 65,640,477 66,547,919 422,020,892 Interest expense 19,932,015 16,317,869 12,490,260 Loss on warrant liability 1,608,973 - - Other expense (income) (668,930) 399,182 559,299 Income (loss) before taxes 109,748,742 (48,490,799) (419,648,713) Income tax expense (benefit) 14,476,821 (5,067,084) 13,090,905 Net income (loss) 95,271,921 (43,423,715) (432,739,618) Less: net income (loss) attributable to noncontrolling interests 43,092,753 2,362,899 (7,959,172) Net income (loss) attributable to Nutex Health Inc. $ 52,179,168 $ (45,786,614) $ (424,780,446) Adjusted EBITDA $ 123,709,142 $ 10,827,681 $ 12,547,923 Year December 31, 2024 Compared to Year December 31, 2023 We reported a net income attributable to Nutex Health Inc. of $52.2 million, or earnings of $9.71 per share, for 2024 as compared with a net loss attributable to Nutex Health Inc. of $45.8 million, or a loss of $10.39 per share, for 2023.
Revenue is recognized and received monthly for our services. In addition, we provide consultant services that are charged as a flat fixed rate and recognized as revenue when the service is performed.
Revenue is recognized and received monthly for our services. In addition, we provide consultant services that are charged as a flat fixed rate and recognized as revenue when the service is performed. Consultant services revenues represent a small portion of our total revenue. Construction in Progress. The Company regularly is in the process of constructing new facilities.
We plan to expand our operations by entering new market areas either through development of new hospitals, formation of new IPAs or by making acquisitions. We expect to open 5 to 10 new hospital facilities by the end of the year 2025.
We plan to expand our operations by expanding our clinical services at our existing facilities, by entering new market areas either through development of new hospitals, formation of new IPAs or by making acquisitions. We expect to open three new hospital facilities by the end of the year 2025. These facilities are either under construction or in advanced planning stages.
A reconciliation of net income to Adjusted EBITDA is included below. Adjusted EBITDA is not intended to serve as an alternative to U.S.
Interest expense includes interest on lease liabilities, which is a component of total finance lease cost. A reconciliation of net income to Adjusted EBITDA is included below. Adjusted EBITDA is not intended to serve as an alternative to U.S.
We also earn management fees under our management services contracts with other IPAs and MSOs which are reported as revenue. The population health management division had $0.4 million of operating income for 2022 since completion of the reverse business combination.
We also earn management fees under our management services contracts with other IPAs and MSOs which are reported as revenue. The population health management division had $1.4 million of operating income for 2024 driven by our divestiture of Procare and Clinigence Health Inc. entities. These two entities were negatively impacting the population health management division’s operating performance.
Because all the Company’s performance obligations relate to contracts with a duration of less than one-year, certain disclosures are limited. The transaction price is determined based on gross charges for services provided, reduced by contractual adjustments provided to third-party payors, discounts and implicit e concessions provided primarily to uninsured patients in accordance with the Company’s policy.
For insured patients, the transaction price is determined based on gross charges for services provided, reduced by adjustments provided to third-party payors, discounts and implicit price concessions provided primarily to uninsured patients in accordance with the Company’s policy. For uninsured patients, the Company recognizes revenue based on established rates, subject to certain discounts and implicit price concessions.
Refer to Non-GAAP Financial Measures discussed below for a definition and reconciliation of Adjusted EBITDA. The items affecting revenue and start-up costs of two new hospitals in 2022 contributed significantly to the decline in Adjusted EBITDA in the 2022 period. A discussion of our segment results is included below. Hospital Division.
Refer to Non-GAAP Financial Measures discussed below for a definition and reconciliation of Adjusted EBITDA. 39 Table of Contents A discussion of our segment results is included below. Hospital Division.
We incur additional annual expenses related to these matters and, among other things, additional directors’ and officers’ liability insurance, director fees, reporting requirements of the SEC, transfer agent fees, hiring additional accounting, legal and administrative personnel, increased auditing and legal fees and similar expenses. In 2022, we recognized a non-cash impairment charge of $398.1 million, as revised, to reduce the carrying amount of goodwill for the population health management division reporting unit acquired in the reverse business combination.
We incur additional annual expenses related to these matters and, among other things, additional directors’ and officers’ liability insurance, director fees, reporting requirements of the SEC, transfer agent fees, hiring additional accounting, legal and administrative personnel, increased auditing and legal fees and similar expenses. Nonoperating items Interest expense.
In 2022, we have made staffing additions commensurate with our operational growth and made key additions to our executive management team. As a public company, we must comply with new laws, regulations and requirements, certain corporate governance provisions of the Sarbanes-Oxley Act of 2002, related regulations of the SEC and the continued listing requirements of the NASDAQ, with which we were not required to comply with as a private company.
General and administrative costs increased $8.6 million attributed to increases in accrued bonus expense ($2.7 million), professional services ($2.3 million), insurance expense ($2.3 million) and in other ($1.3 million). As a public company, we must comply with new laws, regulations and requirements, certain corporate governance provisions of the Sarbanes-Oxley Act of 2002, related regulations of the SEC and the continued listing requirements of the NASDAQ, with which we were not required to comply with as a private company.
Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions. During the three months ended September 30, 2022, we determined that the estimated fair value of our population health management division reporting unit which was acquired in the reverse business combination with Clinigence was less than its carrying value.
No goodwill impairment was recognized for year ended December 31, 2024. On December 31, 2023, we recognized an impairment loss of $1.1 million in a reporting unit within our Hospital Division for the closure of a facility in January 2024. During the three months ended September 30, 2022, we determined that the estimated fair value of our population health management division reporting unit which was acquired in the reverse business combination with Clinigence was less than its carrying value.
As well, there can be no assurance that third-party payors will not attempt to further reduce the rates they pay for our services or that additional rules issued under the NSA will not have adverse consequences to our business. Results of Operations We report the results of our operations as three segments in our consolidated financial statements: (i) the hospital division, (ii) the population health management division and (ii) the real estate division.
Any reduction in the rates that we can charge or amounts we can receive for our services will reduce our total revenue and our operating margins. Results of Operations We report the results of our operations as three segments in our consolidated financial statements: (i) the hospital division, (ii) the population health management division and (iii) the real estate division.
The residual fair value after this allocation was compared to the goodwill balance with the excess goodwill charged to expense. Based on this analysis, we recognized a non-cash impairment charge of $398.1 million, as revised, to reduce the carrying amount of goodwill for the population health management division reporting unit.
Based on this analysis, we recognized a non-cash impairment charge of $398.1 million, as revised, to reduce the carrying amount of goodwill for the population health management division reporting unit. We believe the estimates and assumptions utilized in our impairment testing are reasonable and are comparable to those that would be used by other marketplace participants.
In determining the appropriate valuation allowance, the Company considered the projected realization of tax benefits based on expected levels of future taxable income, available tax planning strategies and reversals of existing taxable temporary differences. Year Ended December 31, 2022 Compared to Year Ended December 31, 2021 We reported a net loss attributable to Nutex Health Inc. of $424.8 million, or a loss of $0.67 per share, for 2022 as compared with net income attributable to Nutex Health Inc. of $132.6 million, or $0.22 per diluted share, for 2021.
In determining the appropriate valuation allowance, the Company considered the projected realization of tax benefits based on expected levels of future taxable income, available tax planning strategies and reversals of existing taxable temporary differences. As of December 31, 2024, we recorded a non-cash benefit of $6.5 million to income tax expense to remove the majority of the valuation allowance after we concluded that the associated deferred tax assets would be realizable.
We completed our reverse business combination with Clinigence in April 2022. Clinigence’s operations are reported as the population health management division. Our total revenue for 2022 for this division was $20.8 million consisting of capitation revenue of $15.5 million, management fees of $4.3 million and SaaS revenue of $946 thousand. Capitation revenue is recognized by our consolidated VIE, AHISP.
Legacy Clinigence’s operations are reported as the population health management division. Our total revenue for 2024 for this division was $30.9 million consisting of capitation revenue of $27.8 million, management fees of $2.1 million and SaaS revenue of $1 million. The increase in revenue is attributed to increases in capitation revenue in 2024.
Therefore, Nutex Health Holdco LLC was treated as the accounting acquirer in the merger. Our financial statements presented for periods prior to April 1, 2022 are those of Nutex Health Holdco LLC, as the Company’s predecessor entity.
Therefore, Nutex Health Holdco LLC was treated as the accounting acquirer in the merger.
The non-cash impairment charge reduced the excess carrying amount of goodwill for the population health management division that were greater than its residual fair value.
On June 30, 2024, we determined that the fair value of our Population Health Management Division was greater than its carrying value. Therefore, no goodwill impairment was recognized for the quarter ended June 30, 2024.
Nutex will control the timing and amount of any future sales of its Common Stock and the Investor is obligated to make purchases in accordance with the purchase agreement, subject to various limitations including those under the Nasdaq listing rules. Nutex intends to use the net proceeds from the future sale of its Common Stock for working capital and general corporate purposes to support its growth. In connection with the execution of the Yorkville agreement, the Company issued 1,356,318 shares of Common Stock to the Investor as a commitment fee, in a private transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended. Under the Agreement, issuances of Common Stock may be suspended upon the occurrence of customary events, including the unavailability of the resale registration statement.
Nutex will control the timing and amount of any future sales of its Common Stock and the Investor is obligated to make purchases in accordance with the purchase agreement, subject to various limitations including those under the Nasdaq listing rules.
Strategically, we are focused on the growth of this division principally through the addition of new independent physician associations and have staffed our organization to manage larger numbers of such organizations. Real Estate Division. This division reports the operations of consolidated Real Estate Entities where we provide guarantees of their indebtedness or are co-borrowers.
This strategic move contributed to improved gross margins from 2024 onward, reinforcing the organization's long-term profitability. Real Estate Division. This division reports on the operations of consolidated Real Estate Entities where we provide guarantees of their indebtedness or are co-borrowers.
We recorded a non-cash benefit of $2.4 million to income tax expense to remove the acquired valuation allowance after we concluded that the associated deferred tax assets would be realizable. Each of the discrete items above, as well as the non-deductible goodwill impairment expense also recognized 2022, are one-time, non-cash items. Liquidity and Capital Resources As of December 31, 2023, we had $22.0 million of cash and equivalents, compared to $34.3 million of cash and equivalents at December 31, 2022. Significant sources and uses of cash during 2023. Sources of cash: • Cash from operating activities was $1.3 million. • We received net proceeds of $6.1 million from borrowings under notes payable, lines of credit and convertible notes.
For the year ended December 31, 2022 we recorded a non-cash benefit of $2.4 million to income tax expense to remove the acquired valuation allowance after we concluded that the associated deferred tax assets would be realizable. As of December 31, 2023, a valuation allowance was established against the net deferred tax asset because the Company determined it was more likely than not that future earnings would not be sufficient to realize the corresponding tax benefits.